BICALUTAMIDE IN COMBINATION WITH TRASTUZUMAB/PERTUZUMAB FOR ANDROGEN RECEPTOR (AR) POSITIVE, HER-2 OVER EXPRESSING BREAST CANCER: A CASE STUDY USING NOVEL THERAPY

Pena C.; Suvorava N.; Payne J.; Konala V; Hardwicke F.

首页> 外文期刊>Journal of investigative medicine >BICALUTAMIDE IN COMBINATION WITH TRASTUZUMAB/PERTUZUMAB FOR ANDROGEN RECEPTOR (AR) POSITIVE, HER-2 OVER EXPRESSING BREAST CANCER: A CASE STUDY USING NOVEL THERAPY

【24h】

BICALUTAMIDE IN COMBINATION WITH TRASTUZUMAB/PERTUZUMAB FOR ANDROGEN RECEPTOR (AR) POSITIVE, HER-2 OVER EXPRESSING BREAST CANCER: A CASE STUDY USING NOVEL THERAPY

机译：比卡鲁胺联合曲妥珠单抗/培妥珠单抗治疗过度表达乳腺癌的雄激素受体（AR）阳性HER-2的病例：新疗法案例研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of investigative medicine》 |2015年第2期|共1页
作者
Pena C.; Suvorava N.; Payne J.; Konala V; Hardwicke F.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类诊断学;
关键词

相似文献

外文文献
中文文献
专利

1. BICALUTAMIDE IN COMBINATION WITH TRASTUZUMAB/PERTUZUMAB FOR ANDROGEN RECEPTOR (AR) POSITIVE, HER-2 OVER EXPRESSING BREAST CANCER: A CASE STUDY USING NOVEL THERAPY [J] . Pena C., Suvorava N., Payne J., Journal of investigative medicine . 2015,第2期

机译：比卡鲁胺联合曲妥珠单抗/培妥珠单抗治疗过度表达乳腺癌的雄激素受体（AR）阳性HER-2的病例：新疗法案例研究
2. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population [J] . Shoko Noda-Narita, Akihiko Shimomura, Asuka Kawachi, Breast cancer . 2019,第4期

机译：曲妥珠单抗氨丹宁在先前使用曲妥珠单抗和帕妥珠单抗联合治疗以及仅在日本人群中联合曲妥珠单抗治疗的转移性人类表皮生长因子受体2阳性乳腺癌患者之间的疗效比较
3. Atezolizumab in combination with trastuzumab emtansine or with trastuzumab and pertuzumab in patients with HER2-positive breast cancer and atezolizumab with doxorubicin and cyclophosphamide in HER2-negative breast cancer: Safety and biomarker outcomes from a multi-cohort Phase Ib study [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：atezolizumab与Trastuzumab Omtansine或用曲妥珠单抗和腹腔癌患者的患者与海莫霉素和atezolizumab与海莫霉素和环磷酰胺组合，在Her2阴性乳腺癌中：来自多队阶段IB研究的安全和生物标志物结果
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population [O] . Shoko Noda-Narita, Akihiko Shimomura, Asuka Kawachi, -1

机译：曲妥珠单抗氨丹宁在仅使用过曲妥珠单抗和帕妥珠单抗联合曲妥珠单抗治疗且仅在日本人群中治疗的转移性人类表皮生长因子受体2阳性乳腺癌患者之间的疗效比较
7. Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2–positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study) [O] . Toshinari Yamashita, Hidetoshi Kawaguchi, Norikazu Masuda, 2020

机译：Eribulin，Pertuzumab和Trastuzumab组合治疗人体表皮生长因子受体2阳性晚期或转移性乳腺癌的疗效：多中心，单臂，II期研究（JBCRG-M03研究）
8. Phase II Study of a HER-2/neu (HER2) Intracellular Domain (ICD) Peptide- Based Vaccine Administered to Stage IIIB and IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab Monotherapy; Annual rept. 27 Apr 2007-26 Apr 2008 [R] . Disis, M. L. 2008

机译：对接受曲妥珠单抗单一疗法的IIIB和IV期HER2阳性乳腺癌患者施用HER-2 / neu（HER2）细胞内结构域（ICD）基于肽的疫苗的II期研究;年度报告。 2007年4月27日至2008年4月26日

BICALUTAMIDE IN COMBINATION WITH TRASTUZUMAB/PERTUZUMAB FOR ANDROGEN RECEPTOR (AR) POSITIVE, HER-2 OVER EXPRESSING BREAST CANCER: A CASE STUDY USING NOVEL THERAPY

著录项

相似文献

相关主题

期刊订阅